Compounds for treatment of cancer
The present invention relates to a compound of formula XXII and a compound of formula 17ya, which are defined as anywhere in the specification, to a composition comprising the same, and to a method of using thereof in the treatment of various forms of cancer.
1. A compound represented by formula XXII:
wherein
A is indolyl;
wherein said A is optionally substituted by substituted or unsubstituted O-alkyl, O-haloalkyl, F, Cl, Br, I, haloalkyl, CF 3 , CN, —CH 2 CN, NH 2 , hydroxyl, —(CH 2 ) i NHCH 3 , —(CH 2 ) i NH 2 , —(CH 2 ) i N(CH 3 ) 2 , —OC(O)CF 3 , substituted or unsubstituted —SO 2 -aryl, substituted or unsubstituted C 1 -C 5 linear or branched alkyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted alkylamino, substituted or unsubstituted aminoalkyl, —OCH 2 Ph, substituted or unsubstituted —NHCO-alkyl, COOH, substituted or unsubstituted —C(O)Ph, substituted or unsubstituted C(O)O-alkyl, C(O)H, —C(O)NH 2 , NO 2 or combination thereof; and
i is an integer between 0-5;
R 1 is hydrogen, linear or branched, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, —CH 2 Ph, substituted benzyl, haloalkyl, aminoalkyl, —OCH 2 Ph, substituted or unsubstituted SO 2 -aryl, substituted or unsubstituted —(C═O)-aryl or OH;
or an N-oxide thereof, or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 , or an N-oxide thereof, or a pharmaceutically acceptable salt thereof, wherein said compound is compound 17ya represented by the structure:
3. The compound of claim 1 , or an N-oxide thereof, or a pharmaceutically acceptable salt thereof, wherein said compound is:
4. A pharmaceutical composition comprising a compound according to claim 1 , or an N-oxide thereof, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
5. The pharmaceutical composition of claim 4 , further comprising at least one pharmaceutically active compound useful in the treatment of cancer.
6. A method of treating, suppressing, reducing the severity, reducing the risk, or inhibiting cancer comprising administering a compound of claim 1 to a subject having cancer under conditions effective to treat the cancer.
7. The method of claim 6 , wherein said cancer is selected from the group consisting of prostate cancer, drug-resistant prostate cancer, breast cancer, ovarian cancer, drug-resistant ovarian cancer, skin cancer, melanoma, lung cancer, colon cancer, glioma, leukemia, lymphoma, renal cancer, CNS cancer, uterine cancer, drug-resistant uterine cancer, and combinations thereof.
8. The method of claim 7 , wherein said cancer is melanoma cancer.
9. The method of claim 7 , wherein said cancer is metastatic melanoma.
10. The method of claim 7 , wherein said cancer is prostate cancer.
11. The method of claim 10 , wherein said prostate cancer is drug-resistant prostate cancer.
12. The method of claim 7 , wherein said cancer is ovarian cancer.
13. The method of claim 12 , wherein said ovarian cancer is drug-resistant ovarian cancer.
14. The method of claim 7 , wherein said cancer is uterine cancer.
15. The method of claim 14 , wherein said uterine cancer is drug-resistant uterine cancer.
16. The method of claim 7 , wherein said cancer is lung cancer.
17. The method of claim 7 , wherein said cancer is colon cancer.
18. The method of claim 7 , wherein said administering is carried out in combination with another cancer therapy.
19. A method of treating a drug resistant tumor or tumors comprising administering a compound of claim 1 to a subject suffering from cancer under conditions effective to treat the drug resistant tumor or tumors.
20. The method of claim 19 , wherein said tumor is a melanoma cancer tumor.
21. The method of claim 19 , wherein said tumor is a metastatic melanoma tumor.
22. The method of claim 19 , wherein said tumor is a prostate cancer tumor.
23. The method of claim 19 , wherein said tumor is an ovarian cancer tumor.
24. The method of claim 19 , wherein said tumor is an uterine tumor, breast cancer tumor or glioma tumor.
25. The method of claim 19 , wherein said administering is carried out in combination with another cancer therapy.
26. A method of destroying a cancerous cell comprising providing a compound of claim 1 and contacting the cancerous cell with the compound under conditions effective to kill the cancer cell.
27. A method of inhibiting, preventing, or slowing the progress of vascularization of a tumor comprising administering a compound of claim 1 to a subject having cancer under conditions effective to inhibit, prevent or slow the progress of vascularization of said tumor.
28. The method of claim 27 , wherein said tumor is selected from the group consisting of prostate cancer tumor, drug-resistant prostate cancer tumor, breast cancer tumor, glioma tumor, ovarian cancer tumor, drug-resistant ovarian cancer tumor, skin cancer tumor, melanoma tumor, lung cancer tumor, colon cancer tumor, lymphoma tumor, renal cancer tumor, CNS cancer tumor, uterine cancer tumor, drug-resistant uterine cancer tumor, and combinations thereof.
29. The method of claim 27 , wherein said method further inhibits, prevents, or slows the progress of vascularization of a metastatic tumor.
30. The method of claim 29 , wherein said tumor is selected from the group consisting of prostate cancer tumor, drug-resistant prostate cancer tumor, breast cancer tumor, glioma tumor, ovarian cancer tumor, drug-resistant ovarian cancer tumor, skin cancer tumor, melanoma tumor, lung cancer tumor, colon cancer tumor, leukemia tumor, lymphoma tumor, renal cancer tumor, CNS cancer tumor, uterine cancer tumor, drug-resistant uterine cancer tumor, and combinations thereof.